Lam A, Fernando D, Sirlin C C, Nayyar M, Goodwin S C, Imagawa D K, Lall C
Department of Radiological Sciences, Irvine School of Medicine, University of California, 101 The City Drive South, Orange, CA 92868, USA.
Department of Radiological Sciences, Irvine School of Medicine, University of California, 101 The City Drive South, Orange, CA 92868, USA.
Clin Radiol. 2017 Nov;72(11):994.e9-994.e16. doi: 10.1016/j.crad.2017.07.003. Epub 2017 Aug 2.
To evaluate the utility of the portal venous phase on multiphasic computed tomography (CT) after treatment of hepatocellular carcinoma (HCC) with trans-arterial chemoembolisation (TACE).
This was a retrospective review of patients who underwent TACE for HCC between 1 April 2012 and 21 December 2014, with appropriate multiphasic, pre- and post-procedural CT examinations. The maximum non-contrast, arterial phase, and portal venous phase attenuation values of the tumour and tumour bed were evaluated within a region of interest (ROI), with values adjusted against background hepatic parenchyma. Linear regression analyses were performed for both the arterial and venous phases, to assess the level of enhancement and to determine if the venous phase had additional value in this setting.
A total of 86 cases from 51 patients were reviewed. All pre-procedural CT examinations of lesions demonstrated arterial phase enhancement with portal venous and delayed phase washout compatible with HCC. The post-procedural CT examinations following TACE revealed expected decreased arterial enhancement. Sixty-five cases (76%) showed persistent non-enhancement on the portal venous phase following embolisation therapy. A total of 21 cases (24%), however, demonstrated progressive portal venous hyper enhancement. Linear regression analysis demonstrated a statistical significance between the difference in maximal arterial and portal venous enhancement in these cases.
Following TACE, the treated lesion may demonstrate portal venous phase hyper-enhancement within the tumour bed. As such, full attention should be given to these images for comprehensive evaluation of tumour response following treatment.
评估经动脉化疗栓塞术(TACE)治疗肝细胞癌(HCC)后多期计算机断层扫描(CT)门静脉期的效用。
这是一项对2012年4月1日至2014年12月21日期间因HCC接受TACE治疗且进行了适当的多期、术前和术后CT检查的患者的回顾性研究。在感兴趣区域(ROI)内评估肿瘤和肿瘤床的最大平扫、动脉期和门静脉期衰减值,并根据肝脏实质背景进行调整。对动脉期和静脉期均进行线性回归分析,以评估强化程度并确定静脉期在此情况下是否具有额外价值。
共回顾了51例患者的86个病例。所有病变的术前CT检查均显示动脉期强化,门静脉期和延迟期廓清,符合HCC表现。TACE术后的CT检查显示动脉强化预期下降。65例(76%)在栓塞治疗后的门静脉期显示持续无强化。然而,共有21例(24%)表现为进行性门静脉高强化。线性回归分析显示这些病例中最大动脉强化和门静脉强化的差异具有统计学意义。
TACE治疗后,治疗部位的肿瘤床可能在门静脉期出现高强化。因此,应充分关注这些图像,以全面评估治疗后的肿瘤反应。